Therapeutic resistance is a significant problem in cancer therapy, reducing therapy efficacy and causing disease relapse. The session "Therapeutic Resistance" addresses the mechanisms, clinical significance, and how to overcome resistance in oncology.".
Cancer cells may circumvent treatment by genetic mutation, epigenetic changes, alternative pathway activation, drug efflux, and adaptation to the tumor microenvironment. These processes may make traditional treatments, such as chemotherapy, targeted therapy, and immunotherapy, increasingly less effective with time. It is critical to understand these pathways in order to develop interventions to restore sensitivity and enhance outcomes.
The session discusses novel ways to overcome therapeutic resistance, including combination treatment, adaptive treatment strategies, and new targeted therapies. Biomarker-stratified patient selection, molecular characterization, and real-time assessment enable physicians to recognize resistant tumor subpopulations and modify therapy regimens accordingly. New research also identifies methodologies to avert the generation of resistance, including first-line intervention and tumor microenvironment modulation.
Participants will learn about the biology, clinical issues, and new solutions for therapeutic resistance. This session highlights the need to address resistance to improve the efficacy of treatment, extend survival, and further personalize the care of cancer, ultimately favoring the outcome in patients with refractory or relapsed malignancies.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
